Scarica l'app Stockscreener
6.21
0.32%
-0.02
Precedente Chiudi:
$6.23
Aprire:
$6.26
Volume 24 ore:
998.36K
Relative Volume:
0.97
Capitalizzazione di mercato:
$318.41M
Reddito:
$676.80M
Utile/perdita netta:
$-8.60M
Rapporto P/E:
-21.95
EPS:
-0.2829
Flusso di cassa netto:
$135.40M
1 W Prestazione:
+5.08%
1M Prestazione:
-17.97%
6M Prestazione:
-29.19%
1 anno Prestazione:
-18.61%
Intervallo 1D:
$6.14
$6.30
Intervallo di 1 settimana:
$5.80
$6.60
Portata 52W:
$4.36
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Nome
Emergent Biosolutions Inc
Settore
Telefono
240-631-3200
Indirizzo
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
6.21 | 247.14M | 676.80M | -8.60M | 135.40M | -0.2829 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2024-03-07 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-08-29 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Iniziato | The Benchmark Company | Buy |
| 2021-02-24 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-07-31 | Reiterato | Chardan Capital Markets | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-08-03 | Reiterato | Chardan Capital Markets | Buy |
| 2018-06-13 | Iniziato | Argus | Buy |
| 2018-04-25 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2018-01-16 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Singular Research | Buy |
| 2016-04-15 | Iniziato | Chardan Capital Markets | Buy |
| 2016-03-28 | Iniziato | Singular Research | Buy |
| 2016-02-19 | Iniziato | Wells Fargo | Outperform |
| 2014-05-15 | Iniziato | Summer Street Research | Buy |
| 2011-05-31 | Reiterato | WBB Securities | Strong Buy |
| 2011-01-10 | Reiterato | Wedbush | Outperform |
| 2010-11-05 | Reiterato | Wedbush | Outperform |
| 2010-08-18 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Reiterato | Caris & Company | Buy |
Mostra tutto
Emergent Biosolutions Inc Borsa (EBS) Ultime notizie
EBS Reinstated by JP Morgan -- Current Rating Underweight - GuruFocus
2026-08-21 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Stockholders to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse
JPMorgan Chase & Co. Begins Coverage on Emergent Biosolutions (NYSE:EBS) - MarketBeat
EBS Looks 11.9% Undervalued on GF Value™ Despite Underweight Rat - GuruFocus
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits
Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Emergent (EBS) Price: Gains 4.94% to Reach $4.89 at the Close; Immediate View: the Near-Term Reference Band Stretches From $4.65 to $5.13 on the DayPrice Target - vinanet.vn
Emergent BioSolutions Balances Q2 Beat With Tough Outlook - The Globe and Mail
S&P downgrades Emergent BioSolutions outlook on competition - Investing.com
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
Emergent BioSolutions (EBS) Holds Above Support as Shares Slip 0.33%Volume Oscillator - vinanet.vn
Emergent BioSolutions Inc (EBS) (Q2 2026) Earnings Call Highligh - GuruFocus
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law - Business Wire
Emergent BioSolutions Restructures - Contract Pharma
Emergent BioSolutions (EBS) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Emergent Biosolutions Inc. (NYSE:EBS) Given Average Rating of "Hold" by Analysts - MarketBeat
Q2 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Q4 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Q1 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
American Century group reports 5.4% Emergent BioSolutions (EBS) ownership on Schedule 13G - Stock Titan
Emergent Biosolutions (EBS) Earnings Date and Reports 2026 $EBS - MarketBeat
Levi & Korsinsky Notifies Investors of Pending - GlobeNewswire
Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research - MarketBeat
Emergent BioSolutions (EBS) Gains 2.25% to $4.55, Holding Ground Above Key SupportTPO Profile - vinanet.vn
Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript - AOL.com
EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS) - Business Wire
Emergent BioSolutions (EBS) EVP Stephanie Duatschek details stock and option holdings - Stock Titan
Trade Desk, Papa John's, Emergent BioSolutions Hit 52-Week Lows as Weak Results Trigger Analyst Downgrades - finance.biggo.com
EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions - PR Newswire
EMERGENT BIOSOLUTIONS INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $10 FROM $12 - webull.com
Why Did TTD, PZZA, EBS Stocks Plummet To 52 Week Lows? - Stocktwits
Emergent BioSolutions cuts FY2026 revenue forec... - Pluang
Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS) - PR Newswire
H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
H.C. Wainwright cuts Emergent BioSolutions stock price target on revenue outlook - Investing.com Nigeria
Emergent Biosolutions (NYSE:EBS) Given New $10.00 Price Target at HC Wainwright - MarketBeat
EBS Maintained by HC Wainwright & Co. -- Price Target Lowered to $10 - GuruFocus
Emergent BioSolutions Inc (EBS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Emergent Biosolutions Q2 Earnings Call Highlights - MarketBeat
Emergent BioSolutions Inc (EBS) Stock News Today - TradingKey
Watch Out on Emergent BioSolutions Inc.: Strong Operational Recovery Tempered by Commercial Headwinds and Strategic Reset - Kalkine
Despite Hitting US$5.31, Emergent BioSolutions Insiders Still Sold Too Soon - Moomoo
Pacer Advisors Inc. Purchases Shares of 416,191 Emergent Biosolutions Inc. $EBS - MarketBeat
Emergent BioSolutions Inc. (EBS): Investor Outlook Reveals 125.99% Potential Upside - DirectorsTalk Interviews
Dimensional Fund Advisors LP Has $22.88 Million Position in Emergent Biosolutions Inc. $EBS - MarketBeat
Emergent BioSolutions Shares Plunge After 2026 Guidance Cut, Restructuring - Moomoo
Emergent BioSolutions Announces Restructuring Amid Turnaround Efforts - The Globe and Mail
Emergent BioSolutions laying off dozens, shedding real estate as Narcan competition strains profits - The Business Journals
Emergent BioSolutions | 10-Q: Q2 2026 Earnings Report - Moomoo
Emergent Bio stock slips despite Q2 beat (EBS:NYSE) - Seeking Alpha
Emergent BioSolutions Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Emergent Biosolutions Inc Azioni (EBS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.66%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):